Abscopal effect following palliative radiotherapy after cemiplimab in recurrent cervical cancer: a case report Authors: Chihiro Mano, Michihiro Tanikawa, Misako Kusakabe, Reiko Nakamura, Yasunori Yoshino, Keiko Murofushi, Nao Kino Published: 2026 ABSTRACT BackgroundThe abscopal effect is a rare phenomenon in which localized radiotherapy induces regression of distant, non-irradiated metastatic lesions through systemic immune activation. Although immune checkpoint inhibitors may enhance this response, reports in recurrent cervical cancer remain limited.Case PresentationA 56-year-old woman with stage IVA squamous cell carcinoma of the cervix underwent definitive concurrent chemoradiotherapy. Six months later, computed tomography (CT) revealed recurrence with para-aortic lymph node, liver, and lung metastases. Following systemic chemotherapy, she received three cycles of cemiplimab; however, progressive disease developed, including new bone metastases. Palliative radiotherapy was administered to the symptomatic bone lesions. Three months after radiotherapy, follow-up CT demonstrated marked regression of the liver and lung metastases outside the irradiated field, consistent with an abscopal effect. Based on this favorable systemic response, cemiplimab therapy was resumed. The clinical course suggests that radiotherapy may have enhanced systemic antitumor immunity in the setting of prior PD-1 blockade.ConclusionThis case demonstrates a radiographically significant abscopal effect following palliative radiotherapy after cemiplimab therapy in recurrent cervical cancer. The combination of radiotherapy and immune checkpoint inhibition may provide synergistic antitumor activity; however, further studies are needed to determine its clinical significance and optimal use in advanced gynecologic malignancies. Further studies are warranted to clarify the mechanisms, predictive biomarkers, and optimal treatment sequencing to maximize the likelihood of inducing the abscopal effect. Introduction Despite the widespread implementation of cervical cancer screening and human papillomavirus vaccination, approximately 6% of patients present with metastatic disease (Lin et al., 2019). Meanwhile, approximately one-third of patients treated with concurrent chemoradiotherapy followed by brachytherapy for locally advanced disease experience disease recurrence or progression (Pötter et al., 2021). Advanced or recurrent cervical cancer is generally not amenable to curative local therapies and is associated with poor prognosis. Systemic treatment for advanced or recurrent cervical cancer has evolved from cisplatin monotherapy to combination therapy with paclitaxel and a platinum agent such as cisplatin or carboplatin. Subsequently, bevacizumab was incorporated into treatment regimens, and more recently, immune checkpoint inhibitors (ICIs)—including pembrolizumab and cemiplimab—have been introduced (Gennigens et al., 2022). More recently, ICIs have become an important component of treatment for cervical cancer. Pembrolizumab in combination with concurrent chemoradiotherapy, followed by pembrolizumab maintenance, is used for patients with high-risk locally advanced cervical cancer (KEYNOTE-A18) (Lorusso et al., 2024). For recurrent or metastatic disease, pembrolizumab in combination with platinum-based chemotherapy with or without bevacizumab is a first-line treatment option for patients with PD-L1-positive tumors (KEYNOTE-826) (Monk et al., 2023), whereas cemiplimab is an option for patients with disease progression after platinum-based chemotherapy (EMPOWER-Cervical 1) (Tewari et al., 2022). Radiotherapy serves as a cornerstone of concurrent chemoradiotherapy with curative intent. It is also actively employed in recurrent settings, including oligometastatic disease, and for palliative management of widespread metastases. Cervical cancer, particularly squamous cell carcinoma (SCC), exhibits high radiosensitivity (Ollivier et al., 2023). In radiotherapy for malignancies, the rare phenomenon in which distant metastatic lesions regress outside the radiation field is known as the abscopal effect. Although the abscopal effect has traditionally been described mainly in case reports, recent prospective studies have provided further evidence of this phenomenon. This effect has been increasingly reported in recent years owing to the widespread use of ICIs. This case report describes recurrent cervical cancer in which palliative radiotherapy administered following cemiplimab resulted in the regression of distant metastatic lesions outside the irradiated field. Case presentation The patient was a 56-year-old woman (gravida 2 para 2) who had undergone menopause at the age of 50 years and had no significant past medical history. In April of year X-2, she developed lower abdominal pain, vaginal bleeding, and urinary incontinence, prompting referral to a gynecologist. Histological examination confirmed squamous cell carcinoma. She was subsequently referred to our hospital in June of the same year. A vaginal speculum examination revealed a hemorrhagic neoplastic lesion arising from the cervix. On bimanual examination, a mass was palpated along the anterior vaginal wall extending from the 9 o'clock to the 12 o'clock position, with invasion limited to the lower third of the vagina. Bilateral parametrial involvement was also observed. Transvaginal ultrasonography identified a 48-mm mass in the left anterior cervix. Histological examination of the cervical lesion confirmed squamous cell carcinoma (Fig. 1). Contrast-enhanced chest–abdomen–pelvis CT revealed a cervical tumor causing bilateral ureteral obstruction with resultant hydronephrosis. Bladder invasion and metastasis to the right obturator lymph node were suspected. The left ovary was enlarged, although no evidence of distant metastases was identified. Pelvic magnetic resonance imaging demonstrated a markedly enlarged cervix. The normal cervical structure was completely replaced by tumor tissue, which exhibited moderately low signal intensity on T2-weighted images. The tumor measured over 7 cm in length and extended to the posterior bladder wall, right pelvic wall, and bilateral ureters. The right obturator lymph node exhibited marked diffusion restriction, consistent with metastatic disease. Positron emission tomography-CT demonstrated intense fluorodeoxyglucose uptake in the cervical tumor, with a maximum standardized uptake value of 19.02. Additional uptake was observed in the right obturator and right common iliac lymph nodes, consistent with lymph node metastases. Laboratory testing revealed an elevated SCC antigen level of 10.3 ng/mL. Based on histological findings, clinical examination, and multimodal imaging, a diagnosis of stage IVA cervical cancer (T4aN1M0), squamous cell carcinoma, was established.Fig. 1Histopathological findings of an extended biopsy specimen obtained from the uterine cervical tumor, demonstrating squamous cell carcinoma on hematoxylin and eosin staining.Fig. 1 Histopathological findings of an extended biopsy specimen obtained from the uterine cervical tumor, demonstrating squamous cell carcinoma on hematoxylin and eosin staining. Bilateral ureteral stents were placed in June X-2, followed by the initiation of concurrent chemoradiotherapy in July. Chemotherapy comprised six cycles of cisplatin (30 mg/m2). Brachytherapy was recommended as the standard-of-care boost; however, the patient declined brachytherapy. Therefore, radiotherapy consisted of whole pelvic irradiation at 45 Gy in 25 fractions, followed by a stereotactic body radiotherapy boost of 21 Gy in 3 fractions, delivered between July and September. Tumor regression was achieved, with a reduction in serum SCC antigen to 2.4 ng/ml (Fig. 2). Comprehensive genomic profiling performed in December X-2 revealed microsatellite stability and a tumor mutation burden of 8 mut/Mb, with no actionable alterations identified. The patient was followed with regular outpatient visits. In March X-1, serum SCC antigen increased to 5.6 ng/ml, and contrast-enhanced CT performed later that month revealed metastases to the para-aortic lymph node, liver segment S7, and lung segment S3, consistent with disease recurrence. From May to October X–1, six cycles of combination chemotherapy with paclitaxel and carboplatin were administered. However, progressive disease was observed. From February X–1 to March X, three cycles of single-agent irinotecan therapy were administered; however, further disease progression was noted. Subsequently, cemiplimab monotherapy was initiated and administered for three cycles from May to July X. Progressive disease was observed after the third cycle, with worsening liver metastasis and the emergence of new bone metastases (Fig. 3B). Meanwhile, multiple lymph node and lung metastases remained stable. Palliative radiotherapy (20 Gy in 5 fractions) was delivered to the thoracolumbar (Th10–L1) bone metastases. The radiation fields overlapped only at the L1 level, where the previous para-aortic radiation field had delivered 30 Gy in 10 fractions. The spinal cord dose at L1 from the previous irradiation was approximately 15 Gy. Before re-irradiation, the previous dose distribution and doses to the spinal cord and surrounding organs at risk were reviewed, and re-irradiation was considered feasible. Three months later, CT demonstrated an abscopal effect, with regression of non-irradiated liver and lung metastases (Fig. 4A–C). Cemiplimab was resumed for three cycles; however, treatment was discontinued due to progression of liver and lung metastases and the development of new bone lesions.Fig. 2Clinical course of the patient and temporal changes in squamous cell carcinoma antigen. RT: radiotherapy, TC: paclitaxel plus carboplatin.Fig. 2Fig. 3(A) Irradiation field targeting metastatic lymph nodes. (B) Irradiation field targeting bone metastases.Fig. 3Fig. 4Radiological findings of metastatic lesions before cemiplimab treatment, after cemiplimab administration, and following palliative radiotherapy for bone metastases. (A) Bone metastasis involving the twelfth thoracic vertebra. (B) Hepatic metastatic lesions. (C) Multiple pulmonary metastases.Fig. 4 Clinical course of the patient and temporal changes in squamous cell carcinoma antigen. RT: radiotherapy, TC: paclitaxel plus carboplatin. (A) Irradiation field targeting metastatic lymph nodes. (B) Irradiation field targeting bone metastases. Radiological findings of metastatic lesions before cemiplimab treatment, after cemiplimab administration, and following palliative radiotherapy for bone metastases. (A) Bone metastasis involving the twelfth thoracic vertebra. (B) Hepatic metastatic lesions. (C) Multiple pulmonary metastases. Discussion In radiotherapy for malignant tumors, the shrinkage of metastatic lesions outside the irradiated field, known as the abscopal effect, was initially proposed by Robin Mole in 1953 (Mole, 1953). Tumor cell death induced by radiotherapy occurs through both direct and indirect mechanisms. Direct effects include apoptosis and mitotic cell death, whereas indirect effects involve immune-mediated tumor cell death triggered by radiation-induced antitumor immunity. Radiotherapy has been shown to induce immunogenic cell death, in which irradiated tumor cells undergo non-classical apoptosis and release immunostimulatory signals that activate antigen-presenting cells and promote cross-priming of antigen-specific adaptive immune responses (Galluzzi et al., 2013). Damage-associated molecular pattern molecules released from tumor cells activate antigen-presenting cells, including dendritic cells, which process and present tumor-associated antigens to CD8+ cytotoxic T cells. Indirect tumor cell death at the irradiated site occurs when antigen-presenting cell–activated cytotoxic T cells mediate local tumor cell destruction. The abscopal effect arises when these activated cytotoxic T cells exert antitumor activity against tumor cells outside the irradiated field (Ollivier et al., 2023; Lippert and Greenberg, 2021; Jin and Wang, 2021). The abscopal effect is rare, with only 51 cases reported between 1973 and 2019 (Pevzner et al., 2021). Among these cases, malignant melanoma was the most frequently observed primary tumor (33%), and the lung was the most common site of metastatic lesions demonstrating an abscopal effect (41%). Of the 51 cases, 27 received combined radiotherapy and immunotherapy. Recently, reports of abscopal effects following radiotherapy in combination with ICIs have increased, suggesting potential therapeutic synergy. Emerging clinical evidence supports this potential interaction in cervical cancer. In a prospective phase II multi-institutional study of 21 patients with metastatic, recurrent, or persistent cervical cancer, an objective response in non-irradiated lesions was observed in 8 patients (38%) following SBRT and atezolizumab (Ahmed et al., 2026). In addition, a retrospective study of 65 patients with recurrent or metastatic cervical cancer showed that the combination of ICIs and palliative radiotherapy was associated with complete response and higher 36-month PFS (73.7% vs. 33.8%) and OS (85.7% vs. 38.7%) rates compared with ICIs without palliative radiotherapy (Pan et al., 2024). ICIs are thought to enhance the antitumor effects of radiotherapy by promoting cytotoxic T-cell amplification, potentially contributing to the abscopal effect (Sharabi et al., 2015). Previous studies have shown that cytotoxic T-lymphocyte-associated protein 4 inhibitors promote T-cell proliferation. Meanwhile, programmed death-ligand 1 (PD-L1) inhibitors reduce T-cell exhaustion and further enhance T-cell proliferation (Twyman-Saint Victor et al., 2015). In clinical practice, abscopal effects have been reported in patients with lung cancer, urothelial carcinoma, malignant melanoma, gastric cancer, and other malignancies treated with combined ICI and radiotherapy. In urothelial carcinoma, radiotherapy to lung metastases following ICI treatment resulted in complete resolution of non-irradiated brain metastases, with no recurrence observed for 48 months (Kono et al., 2023). In this case, the interval between confirmation of the abscopal effect and disease recurrence was approximately four months. Although an association between the abscopal effect and immune memory has been suggested, its role as a predictive biomarker for the efficacy of ICI rechallenge remains unestablished. A previous case report described a patient with non–small cell lung cancer who developed an abscopal effect after radiotherapy alone and subsequently achieved long-term disease control following ICI administration at the time of recurrence (Morita et al., 2022). In that case, progression of the primary tumor in the left upper lobe was observed 26 months after the initiation of radiotherapy. At that time, biopsy demonstrated a marked increase in the PD-L1 tumor proportion score to 100%, compared with 30% in the initial biopsy. The patient subsequently received pembrolizumab, a programmed cell death protein 1 inhibitor, and remained alive with a progression-free survival of 8 months. These findings suggest that systemic immune responses may occur in patients who develop an abscopal effect, providing a potential biological rationale for ICI rechallenge. In the present case, cemiplimab rechallenge was administered following the observation of an abscopal effect. The decision to rechallenge with cemiplimab was based on the systemic tumor regression observed after palliative radiotherapy, including regression of non-irradiated lesions. This response raised the possibility that radiotherapy had reactivated or enhanced antitumor immunity and potentially restored sensitivity to immune checkpoint blockade. Therefore, despite the previous disease progression during cemiplimab treatment, rechallenge with the same agent was considered reasonable rather than switching to another immune checkpoint inhibitor. In addition, cemiplimab had been previously tolerated without significant toxicity. Although observation alone was also a possible option following the abscopal response, cemiplimab was resumed with the aim of maintaining or augmenting the radiotherapy-induced systemic immune response. However, whether the abscopal effect can serve as a predictive marker for ICI rechallenge efficacy remains unclear, and robust evidence is still lacking. Therefore, further accumulation of clinical evidence is required. In the present patient, palliative radiotherapy for local control of bone metastases induced an abscopal effect in distant, non-irradiated lesions. Bone metastases are typically treated with fractionated radiotherapy, such as 30 Gy in 10 fractions or 20–25 Gy in 4–5 fractions (Ratanatharathorn et al., 1999). Previous studies on the abscopal effect have suggested that hypofractionated regimens (5–20 Gy per fraction) may be more effective than conventional low-dose fractionation (1.8–2.2 Gy per fraction) when combined with ICI (Sharabi et al., 2015). However, excessively high single doses may be disadvantageous, as they can damage normal tissues and induce apoptosis of CD8-positive T cells. Some case reports therefore recommend moderate hypofractionation, such as 8–10 Gy per fraction administered one to three times (Buchwald et al., 2018). In the present case report, palliative radiotherapy for bone metastases was delivered at 20 Gy in 5 fractions. The development of an abscopal effect in this setting demonstrates that such a response can occur with a conventional palliative fractionation schedule when used in the context of ICI therapy. The timing of ICI administration relative to radiotherapy has been investigated in several studies. Preclinical data suggest that concurrent initiation of ICI and radiotherapy yields superior antitumor effects compared with sequential administration (Sharabi et al., 2015). Even when concurrent treatment is not feasible, ICI administration within 6 days after fractionated radiotherapy is more effective than initiation beyond seven days (Dovedi et al., 2017). A clinical study comparing ICI administration within four weeks of radiotherapy versus later administration for brain metastases in patients with malignant melanoma demonstrated greater tumor shrinkage in the group receiving ICIs within four weeks (Qian et al., 2016). Some case reports suggest that radiotherapy should precede anti-PD-1 or anti-PD-L1 inhibitor administration when concurrent treatment is not feasible (Buchwald et al., 2018). In the present case report, the abscopal effect may have resulted from ICI administration followed by radiotherapy. This finding differs from previous basic and clinical studies; however, abscopal effects following radiotherapy administered after ICI treatment have been documented in patients with other cancer types (Nakamura et al., 2021). Further investigation is warranted to clarify optimal radiation delivery methods and the timing of ICI administration. A potential limitation of this case is that pseudoprogression associated with cemiplimab cannot be completely excluded. Pathological confirmation was not performed to establish that the enlargement of the liver metastasis during cemiplimab treatment represented true disease progression. However, the simultaneous development of new bone metastases supported the assessment of progressive disease. Furthermore, regression of the non-irradiated liver and lung metastases was observed after palliative radiotherapy, supporting a temporal association between radiotherapy and the subsequent systemic tumor response. Collectively, these findings were considered consistent with an abscopal effect, although the possibility of pseudoprogression cannot be entirely ruled out. Despite emerging clinical evidence, the abscopal effect in gynecological malignancies remains incompletely understood, particularly regarding its predictors and optimal treatment strategy. High lymphocyte counts, neoantigens, bone marrow-derived immunosuppressive cells, and natural killer cells following radiotherapy have been proposed as biomarkers for predicting the abscopal effect (Nelson et al., 2023). Further research and case accumulation may help identify patient groups susceptible to the abscopal effect and establish treatment methods, such as radioimmunotherapy. Conclusions Although evidence remains limited, clinicians should recognize that even palliative radiotherapy administered after an immune checkpoint inhibitor may induce systemic antitumor responses. In this case, the systemic tumor response observed after radiotherapy provided the rationale for rechallenging with cemiplimab despite prior disease progression during cemiplimab treatment. Such observations warrant prospective investigation of optimal sequencing strategies between radiotherapy and immunotherapy. CRediT authorship contribution statement Chihiro Mano: Writing – original draft, Investigation, Data curation, Conceptualization, Writing – review & editing. Michihiro Tanikawa: Writing – review & editing, Writing – original draft, Supervision, Funding acquisition, Data curation, Conceptualization. Misako Kusakabe: Writing – review & editing, Investigation. Reiko Nakamura: Writing – review & editing. Yasunori Yoshino: Writing – review & editing. Keiko Murofushi: Writing – review & editing, Validation, Data curation. Nao Kino: Writing – review & editing, Supervision. Ethics declaration Informed consent and patient details Written informed consent to take part in the study and to publish the article has been obtained from all participants or their legal representatives. The privacy rights of participants have been observed. Human and biological material This study included organ or tissue donors. This study includes human biological material and consent was obtained by donors, or their next of kin or legal representatives, for use in this study and for publication of the article. The samples used in this research were not sourced from executed prisoners or prisoners of conscience. Studies in Human This study was performed in compliance with relevant laws, regulatory frameworks and guidelines where the research took place. Ethics committee approval was not required under relevant laws and institutional guidelines. Ethics approval was not required for this single-patient case report in accordance with applicable institutional guidelines. Written informed consent was obtained from the patient for publication of the case report and accompanying images. Case Reports This research follows the CARE guidelines and the CARE checklist. Funding This work was supported by the 10.13039/501100001691Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (JSPS KAKENHI; grant number: 23 K08814). Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:(Michihiro Tanikawa reports financial support was provided by the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper).